不同基因型慢性丙型肝炎患者血清HCV-RNA与载脂蛋白B的关系

目的研究慢性丙型肝炎基因1型和非基因1型患者血清HCV—RNA水平和血清载脂蛋白B（ApoB）的关系。方法临床确诊为慢性丙型肝炎的53例患者，采用干扰素联合利巴韦林抗病毒治疗至少24周，Simmonds酶切分型方法进行HCV基因分型，荧光定量聚合酶链反应法（FQ—PCR）定量检测HCV—RNA，全自动生化分析仪检测血清载脂蛋白B，对不同基因型患者血清HCV-RNA水平和载脂蛋白B的关系进行研究分析。结果基因1型和非基因1型慢性丙型肝炎患者的血清HCV-RNA及载脂蛋白B水平差异无统计学意义（P〉0．05）；基因1型患者血清载脂蛋白B水平与HCV—RNA载量无明显相关（P〉0．05）；非基因1型患者血清载脂蛋白B水平随着HCV-RNA载量的降低呈升高趋势（P〈0．05）。结论不同基因型HCV对干扰素产生不同的应答反应，感染HCV基因1型的患者对干扰素治疗应答率显著低于基因2型和3型。不同基因型HCV感染者血清载脂蛋白B无显著差异，血清ApoB水平在非基因1型患者与干扰素抗HCV应答密切相关。

The relationship between HCV-RNA levels and serum ApoB levels in different genotype of HCV

Objective To probe the relationship between HCV-RNA levels and serum ApoB levels in different genotype of HCV patients. Methods Fifty-three patients diagnosed as chronic hapatitis of C were treated by IFN and Ribavirin for at least 24 weeks. Serum HCV-RNA was detected by fluorescent quantitative PCR. Genotype was determined by Simmonds. Results There was no difference of HCV-RNA levels in different genotypes, as that of ApoB. Serum ApoB levels increased along with HCV-RNA decreasing after treated by IFN for 24 weeks in non 1 genotype, but serum ApoB levels had no significant correlation with serum HCV-RNA levels in 1 genotype. Conclusion These results suggest that genotype has been identified as a major predictor of response to interferon-based antiviral therapy, and response rates for genotype 1 are lower than genotype 2 and genotype 3. There is no difference of serum ApoB levels in different genotypes. However, the changing serum ApoB levels and response rates have close correlation treatment with antiviral therapy.